Recurrent Clostridium difficile infection: From colonization to cure

被引:74
|
作者
Shields, Kelsey [1 ]
Araujo-Castillo, Roger V. [2 ]
Theethira, Thimmaiah G. [1 ]
Alonso, Carolyn D. [2 ]
Kelly, Ciaran P. [1 ]
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA
关键词
Antibiotic; Fecal microbiota therapy; Infection control; Infectious diarrhea; Nosocomial infection; Toxin; FECAL MICROBIOTA TRANSPLANTATION; IN-VITRO ACTIVITIES; ANTIBIOTIC-ASSOCIATED DIARRHEA; RISK-FACTORS; DOUBLE-BLIND; TOXIN-A; PSEUDOMEMBRANOUS COLITIS; BINARY TOXIN; INTESTINAL MICROBIOTA; TREATMENT STRATEGIES;
D O I
10.1016/j.anaerobe.2015.04.012
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Clostridium difficile infection (CDI) is increasingly prevalent, dangerous and challenging to prevent and manage. Despite intense national and international attention the incidence of primary and of recurrent CDI (PCDI and RCDI, respectively) have risen rapidly throughout the past decade. Of major concern is the increase in cases of RCDI resulting in substantial morbidity, morality and economic burden. RCDI management remains challenging as there is no uniformly effective therapy, no firm consensus on optimal treatment, and reliable data regarding RCDI-specific treatment options is scant. Novel therapeutic strategies are critically needed to rapidly, accurately, and effectively identify and treat patients with, or at-risk for, RCDI. In this review we consider the factors implicated in the epidemiology, pathogenesis and clinical presentation of RCDI, evaluate current management options for RCDI and explore novel and emerging therapies. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:59 / 73
页数:15
相关论文
共 50 条